C
아미코젠
092040KOSDAQ기타 식품 제조업41.5 / 100
Reference Date: 2026-04-13
Financial Score4.0 / 40
News Sentiment17.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Surged 40.8% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Amicozen is an industrial biotech company specializing in developing enzymes for antibiotic production and health care materials using its proprietary gene evolution technology. Key products include N-acetylglucosamine, phytin, and collagen peptides, with expansion into endolysin enzyme business through collaboration with Lysando AG since 2020.
Number of Employees
228people
Average Salary
49.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 13.534.0Point
PBR
1.42Industry Average 0.640.0Point
2.2x industry avg (risky)
ROE
-27.74Industry Average 2.720.0Point
Well below industry avg
Debt Ratio
57.69Industry Average 11.910.0Point
4.8x industry avg (risky)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼33.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼293.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -22.7% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 70
- Neutral[시대리포트]"대표에서 물러나세요" 주주가치 vs 경영간섭, 행동주의....
혁신기업들이 주주 행동주의의 영향권에 들어왔다는 일반적인 뉴스이며, 아미코젠에 대한 직접적인 행동주의 언급은 없습니다.
Detailed Momentum
52-week position3.0Point
52w lower range (21%)
Current 1,928Won52-week high 4,69052-week low 1,175
1-month return6.0Point
1m +40.83% (strong rise)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
8 totalPositive 0Neutral 8Negative 0
- Neutral정기주주총회결과2026-03-31
- Neutral사업보고서 (2025.12)2026-03-23
- Neutral감사보고서제출2026-03-23
- Neutral[기재정정]의결권대리행사권유참고서류2026-03-18
- Neutral[기재정정]주주총회소집공고2026-03-18